|
|
||||||||
Division of Cardiovascular Surgery, Toronto General Hospital, 4N-470, 200 Elizabeth St, Toronto, ON, Canada M5G 2C4
(Email: danny.spiegelstein@gmail.com; ckim@utoronto.ca; terry.yau@uhn.on.ca).
| The first 20% of the full text of this article appears below. |
The beneficial effects of endothelial progenitor cell (EPC) transplantation in various animal experimental studies have been promising, but have shown limited transferability to human clinical trials. There are a few reports evaluating the reduced number and functional capacity of EPCs due to advanced donor age and other comorbidities [1, 2]. Another major issue of EPCs is the limited number of cells that can be obtained for ex vivo expansion for subsequent autologous cell transplantation.
In the current study, Mieno and colleagues [3] evaluated
Related Article
Ann. Thorac. Surg. 2008 85: 1361-1366.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |